Table 2 Correlation between SREBP1 expression and the clinicopathological features of ovarian cancer.
From: SREBP1 knockdown triggers ferroptosis by suppressing the Nrf2-XCT/GPX4 axis in ovarian cancer
Variables | No. of cases | SREBP1 positive cases | χ2 | p-value |
|---|---|---|---|---|
Age (years) | ||||
≤50 | 47 | 36 | 0.616 | 0.432 |
>50 | 58 | 48 | ||
Deficiency | 1 | |||
Type of pathology | ||||
Plasma tumor | 73 | 63 | 5.515097 | 0.018* |
Mucinous tumor | 33 | 22 | ||
Deficiency | 0 | |||
TNM clinical stage | ||||
Ⅰ | 22 | 17 | 0.296028 | 0.586 |
Ⅱ–Ⅳ | 63 | 52 | ||
Deficiency | 21 | |||
Tumor size (cm) | ||||
≤3 | 4 | 4 | 1.02699 | 0.31 |
>3 | 102 | 81 | ||
Deficiency | 0 | |||
Clinical staging | ||||
T1 | 25 | 5 | 0.178464 | 0.672 |
T2–3 | 59 | 15 | ||
Deficiency | 2 | |||
Lymph node metastasis | ||||
+ | 25 | 24 | 4.915269 | 0.026* |
– | 79 | 60 | ||
Deficiency | 2 | |||
Distant metastasis | ||||
+ | 20 | 19 | 3.228481 | 0.072 |
– | 84 | 65 | ||
Deficiency | 2 | |||
Tumor recurrence | ||||
+ | 18 | 15 | 0.092137 | 0.761 |
– | 86 | 69 | ||
Deficiency | 2 | |||
Ki67 | ||||
<30% | 40 | 28 | 5.095698 | 0.023* |
≥30% | 53 | 47 | ||
Deficiency | 13 | |||
PDL1 | ||||
<3% | 58 | 40 | 7.787774 | 0.005** |
≥3% | 40 | 37 | ||
Deficiency | 8 | |||
